Venus Remedies Ltd

AGM Details

• Date, time, mode: 20 August 2026 at 11:30 AM via VC/OAVM.
• Record date: 13 August 2026.

Key Resolutions

• Ordinary: Receive, consider and adopt standalone financial statements for year ended 31 March 2026.
• Ordinary: Final dividend of Rs 10 per equity share.
• Ordinary: Re-appoint Ashutosh Jain as director by rotation.
• Ordinary: Re-appoint Peeyush Jain as director by rotation.
• Ordinary: Re-appoint Manu Chaudhary as Joint Managing Director for five years.
• Ordinary: Re-appoint Saransh Chaudhary as director for five years.
• Ordinary: Appoint Dr. Gurminder Singh as Non-Executive Independent Director for five years.
• Ordinary: Appoint Dr. Savita Gupta as Non-Executive Independent Director for five years.
• Special: Alter Memorandum of Association.
• Special: Adopt new Articles of Association.

Voting Results

• All resolutions passed with requisite majority.
• No resolution failed; no significant dissent noted.

Dividend

• Final dividend of Rs 10 per equity share approved.

Director Changes

• Re-appoint Ashutosh Jain as director by rotation.
• Re-appoint Peeyush Jain as director by rotation.
• Re-appoint Manu Chaudhary as Joint Managing Director for five years.
• Appoint Saransh Chaudhary as Director for five years.
• Appoint Dr. Gurminder Singh as Non-Executive Independent Director for five years.
• Appoint Dr. Savita Gupta as Non-Executive Independent Director for five years.

Auditors

• Remuneration of cost auditor for financial year 2026-27 ratified.

Material Related Party Transactions

• No material related party transactions disclosed in AGM.

Other Material Approvals

• Special resolutions to alter Memorandum and Articles of Association approved.

Venus Remedies Limited AGM filing chunk contains no extractable details

Venus Remedies Ltd AGM filing excerpt contains no extractable AGM details

Executive Director appointment

• Appointed Saransh Chaudhary as Executive Director (Whole-time) for 5 years from 26 May 2026.
• Profile: heads R&D and operations; M.Sc., M.Phil, Ph.D.; 30+ years in pharma.
• Related to multiple directors on the board.

Non-Executive Independent Director appointment

• Appointed Dr. Gurminder Singh Bedi as Non-Executive Independent Director for 5 years from 26 May 2026.
• Not related to any board member.
• Profile: B.Tech, M.E., PhD; 35+ years; Professor at UIET, Panjab University.

Joint Managing Director re-appointment

• Re-appointed Dr. Manu Chaudhary as Joint Managing Director for five years from 1 October 2026.
• Profile: Head of R&D and operations; Genetics Ph.D.; 30+ years in pharma; led Baddi facility.
• Not related to any board member.

Non-Executive Independent Director re-appointment

• Re-appointed Dr. Savita Gupta as Non-Executive Independent Director for second five-year term from 29 December 2026.
• Profile: Orthopaedic surgeon; 33 years post-MS; Gold Medalist.
• Not related to any board member.

AGM Details

• Date: 20 August 2026; Time: 11:30 am; Mode: VC/OVAM.
• Attendance: 59 members via VC/OVAM.
• E-voting window: 17 Aug 2026 09:00 IST to 19 Aug 2026 17:00 IST.
• Scrutiniser appointed: Prince Chadha.

Key Resolutions

• Adopt standalone financial statements for year ended 31 March 2026.
• Adopt consolidated financial statements for year ended 31 March 2026.
• Declare final dividend of Rs. 10 per equity share.
• Re-appoint Ashutosh Jain as director liable to retire by rotation.
• Re-appoint Peeyush Jain as director liable to retire by rotation.

Voting Status

• Voting results not disclosed in the provided chunk.

Dividend

• Final dividend proposed: Rs 10 per equity share.

Director Changes

• Re-appointment of Ashutosh Jain as director liable to retire by rotation.
• Re-appointment of Peeyush Jain as director liable to retire by rotation.

Financial results

• Unaudited standalone and consolidated quarterly results for quarter ended 30 June 2026 approved.
• Limited Review Reports from statutory auditors accompany the results.
• Trading window closed from 1 July 2026 until 48 hours after results declaration.

MOA/AOA alterations

• Board approved revisions to MOA aligning objects with Companies Act 2013.
• MOA revisions to be placed before members as a Special Resolution at the 37th AGM.
• Annexure A contains revised object clauses; main business remains Pharmaceuticals.

Auditor emphasis of matter

• Emphasis of matter on INR 2,859.72 Lakh share application money in Venus Pharma GmbH.
• Management intends recovery amid European restructuring; ongoing financial support planned.
• Auditor's conclusion not modified.

Consolidated disclosures

• Consolidated results include Venus Pharma GmbH and Venus Pharma Kft; single Pharmaceuticals segment.

Other notes

• Upcoming Special Resolution at 37th AGM; MOA details appended in Annexure A.